Compare Sanofi SA (SNY) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Sprott Uranium Miners ETF — how do they compare? Sanofi SA trades at $40.14 (market cap $95.18B), while Sprott Uranium Miners ETF trades at $46.45 (market cap $1.87B). The key difference: Sanofi SA is far larger — about 50.9× Sprott Uranium Miners ETF's market cap, and Sanofi SA pays a 6.01% dividend while Sprott Uranium Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Sprott Uranium Miners ETF for 61 Days on average.
| SNY | URNM | |
|---|---|---|
Market Cap | $95.18B | $1.87B |
Volume | 2,995,646 | 1,586,926 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $52.34 | $83.99 |
52-Week Low | $39.51 | $46.09 |
Typical Hold Time | 94 Days | 61 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
URNM (Sprott Uranium Miners ETF) trades at $46.43, down 3.01% today amid bearish technical signals. The ETF shows 13 sell signals versus 0 buy signals across moving averages, with oversold RSI readings suggesting potential near-term stabilization. Recent news highlights uranium's strong fundamentals driven by AI power demand and government nuclear investments, though the sector faces volatility from supply-demand imbalances.
Long-term outlook remains positive given nuclear energy's role in AI infrastructure and global decarbonization. Key risks include uranium price volatility and geopolitical supply constraints. Analyst sentiment leans bullish on uranium's structural deficit, with institutional interest growing in pure-play uranium mining exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
